In the United States, Europe and in many other countries, MabThera is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. MabThera is also approved for the treatment of adults in auto-immune diseases: severe active rheumatoid arthritis, pemphigus vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).
In the pediatric population, MabThera/Rituxan is approved in the United States, Europe and other countries for the treatment of previously untreated DLBCL, Burkitt lymphoma/leukemia or Burkitt-like lymphoma as well as GPA/MPA.
In the United States, Japan and Canada, MabThera is marketed as Rituxan.